ASA404 and TNFM-NM-1 treatment in preclinical models of endocrine tumors is associated with differential TNF-R 1 and TLR- 4 M-bM-^@M-^Ssignaling

ABSTRACT: Purpose: ASA404 (Vadimezan) belongs to a class of agents with disrupting properties against tumor vasculature, which is partly mediated by TNFM-NM-1-signaling. Our aim was to investigate the potential therapeutic applicability of ASA404 against endocrine tumors. Experimental Design: We determined anti-tumoral effects in preclinical models of neuroendocrine tumors of the gastroenteropancreatic system [1] and adrenocortical cancer (NCI-H295R) by histology and immunohistochemistry. Furthermore, we characterized these models with their clearly different responsiveness regarding TNFM-NM-1 synthesis and signaling. Results: Upon treatment of tumor bearing mice significant anti-tumoral effects, an increase in TNFM-NM-1 as well as TNFM-NM-1-specific activation of downstream signaling were eviden

ORGANISM(S): Homo sapiens

SUBMITTER: Carsten JM-CM-$ckel 

PROVIDER: E-GEOD-64250 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress